Hyperhidrosis affects approximately 2.8–4.8% of the global population and is a condition that significantly impairs quality of life yet is frequently under-evaluated. Many patients spend years coping with wet underarms, avoiding handshakes, and social isolation — yet highly effective treatments such as botulinum toxin injections, iontophoresis, and surgery where indicated are available today. At Virtuana Clinic in Izmit-Kocaeli, we provide expert assessment for both diagnosis and treatment.
What Is Hyperhidrosis? Definition and Physiology
Normal thermoregulation is a reflex process controlled by the hypothalamus that maintains body temperature between 36.5–37.5 °C. Eccrine sweat glands play the primary role in this process and are activated by signals of heat, exercise, or stress.
Hyperhidrosis is defined as sweating that far exceeds this physiological requirement. Classified as L74.5 in ICD-11, the condition may arise from sympathetic nervous system hyperreactivity (primary) or from a systemic disease (secondary).
Primary vs Secondary Hyperhidrosis: Key Comparison Table
| Feature | Primary Hyperhidrosis | Secondary Hyperhidrosis |
|---|---|---|
| Distribution | Bilateral, symmetric, focal | Generalised |
| Night Sweats | Absent (sweating ceases during sleep) | Frequently present |
| Age of Onset | Pre- or peri-pubescent (<25 years) | Any age (typically adulthood) |
| Family History | Common (30–50%) | Absent |
| Underlying Cause | None (idiopathic sympathetic hyperactivity) | Present (thyroid disorder, diabetes, menopause, medication, tumour) |
| Triggers | Stress, anxiety, heat | Related to disease activity |
| Systemic Symptoms | Absent | May include weight loss, fever, fatigue |
| Treatment Approach | Symptom control (botulinum toxin, iontophoresis, ETS) | Treat underlying cause first |
Primary Focal Hyperhidrosis: Affected Regions
Primary hyperhidrosis presents focally in specific anatomical regions. Epidemiological data shows the following regional distribution:
| Region | Prevalence | Medical Term | Main Impact |
|---|---|---|---|
| Underarms (axillary) | 51% | Axillary hyperhidrosis | Clothing saturation, social isolation |
| Palms (palmar) | 25% | Palmar hyperhidrosis | Difficulty gripping, avoidance of handshakes |
| Soles (plantar) | 26% | Plantar hyperhidrosis | Risk of fungal infection, odour |
| Face / Scalp | 20–22% | Craniofacial hyperhidrosis | Embarrassment in professional/social settings |
| Groin | 9% | Inguinal hyperhidrosis | Skin fold problems, infection risk |
Causes of Secondary Hyperhidrosis
| Category | Specific Causes | Distinguishing Feature |
|---|---|---|
| Endocrine | Hyperthyroidism, diabetes (nocturnal hypoglycaemia), phaeochromocytoma, acromegaly, carcinoid syndrome | Weight loss, palpitations, blood glucose variability |
| Hormonal | Menopause, pregnancy, andropause, hyperprolactinaemia | Hot flushes, predominantly nocturnal sweating |
| Drug-Induced | SSRIs, opioids, antipyretics, tamoxifen, some antihypertensives | Onset concurrent with medication initiation |
| Infectious | Tuberculosis, HIV, endocarditis, brucellosis | Accompanying fever, malaise, weight loss |
| Neurological | Parkinson's disease, spinal cord injury, peripheral neuropathy | Asymmetric sweating, other neurological signs |
| Oncological | Lymphoma (Hodgkin/NHL), solid tumours, leukaemia | Night sweats + B symptoms (fever, weight loss) |
| Other | Obesity, heart failure, chronic anxiety disorder | Identified through general health assessment |
Diagnostic Criteria: Hornberger Criteria
The criteria developed by Hornberger et al. (2004) are the gold standard for diagnosing primary focal hyperhidrosis. The following conditions must be met for diagnosis:
Core criterion: Unexplained, visible excessive sweating persisting for at least 6 months.
At least 2 of the following additional criteria must be present:
- Bilateral and symmetric sweating
- Sufficiently severe to interfere with daily activities
- At least one episode per week
- Age of onset below 25 years
- Positive family history
- Cessation of sweating during sleep
Severity Classification: HDSS Score
The HDSS (Hyperhidrosis Disease Severity Scale) is a 4-point patient-reported outcome measure used to determine treatment indication:
| HDSS Score | Description | Treatment Recommendation |
|---|---|---|
| 1 | Sweating is never noticeable and never interferes with daily activities | Monitoring; no treatment required |
| 2 | Sweating is tolerable but sometimes interferes with daily activities | Medical antiperspirant (aluminium chloride) |
| 3 | Sweating is barely tolerable and frequently interferes with daily activities | Botulinum toxin or iontophoresis indicated |
| 4 | Sweating is intolerable and daily activities are completely disrupted | Botulinum toxin + surgical (ETS) evaluation |
Diagnostic Tools: Minor Test and Gravimetry
Minor Test (iodine–starch test): An iodine solution is applied to the affected area; once dry, starch powder is dusted on. Areas of active sweating turn dark purple to black. Used both for diagnosis and for treatment mapping prior to botulinum toxin injections.
Gravimetry: A filter paper is affixed to the sweating area for a defined period and the weight gain is measured. For axillary hyperhidrosis, a value exceeding 50 mg over 5 minutes is considered clinically significant.
Thermal imaging: A non-invasive technique used in specialised centres that renders sweating areas visible.
Treatment Reference Algorithm
A stepwise approach is recommended in the management of hyperhidrosis:
- Rule out secondary causes: If night sweats, weight loss, or systemic symptoms are present, internal medicine or endocrinology evaluation is warranted.
- Determine severity using HDSS.
- HDSS 2: Begin with 20% aluminium chloride hexahydrate (medical antiperspirant).
- HDSS 3 – Axillary: Botulinum toxin (Botox) injection; duration of effect 6–9 months, standard dose 50 units per axilla.
- HDSS 3 – Palmar/Plantar: Iontophoresis (first-line); botulinum toxin for refractory cases (painful; anaesthesia required).
- HDSS 4 – Refractory: Endoscopic thoracic sympathectomy (ETS) — permanent but carries a risk of compensatory sweating.
Hyperhidrosis Treatment with Botulinum Toxin: Virtuana Clinic Protocol
Botulinum toxin type A is the most effective and highest evidence-level treatment for axillary hyperhidrosis, with FDA approval. After region mapping with the Minor test, 50 units per axilla are administered via intradermal injection. Effect onset occurs within 2–4 weeks, lasting 6–9 months. Repeat sessions follow the same protocol.
For palmar hyperhidrosis, 100–200 units per hand are required; due to pain, a nerve block or anaesthetic cream is essential. For plantar application, the duration of effect is limited to approximately 3–4 months.
Hyperhidrosis Treatment in Izmit: Why Choose Virtuana Clinic?
For hyperhidrosis treatment in Kocaeli/Izmit, Virtuana Clinic offers the following advantages:
- Diagnostic algorithm: Minor test and systematic medical history for primary/secondary differentiation.
- Personalised treatment: Stepwise treatment protocol based on HDSS scoring.
- Botulinum toxin protocol: Standard dose of 50 units per axilla using an FDA-approved preparation, with pre-treatment Minor test mapping.
- Iontophoresis option: Initial and follow-up iontophoresis sessions for palmar and plantar hyperhidrosis.
- Wide geographic access: Conveniently reachable from Gebze, Golcuk, Korfez, Darica, and Sapanca districts.
Cost and Sustainability of Hyperhidrosis Treatment
| Treatment | Frequency | Best-Suited Region |
|---|---|---|
| Aluminium chloride antiperspirant | Daily use | HDSS 2, axillary |
| Iontophoresis (home device) | 1–2 times per week | Palmar/plantar |
| Botulinum toxin (axillary) | 1–2 times per year | Axillary, HDSS 3–4 |
| miraDry | 1–2 sessions (permanent) | Axillary (permanent solution) |
This article is for informational purposes only. Please consult a qualified physician for treatment decisions.